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Abstract (230 words) 
 
Cardiac and cerebrovascular diseases are currently the leading causes of mortality and disability worldwide. 
Both the heart and brain display similar vascular anatomy, with large conduit arteries running on the 
surface of the organ providing tissue perfusion through an intricate network of penetrating small vessels. 
Both organs rely on fine tuning of local blood flow to match metabolic demand. Blood flow regulation 
requires adequate functioning of the microcirculation in both organs, with loss of microvascular function, 
termed small vessel disease (SVD). SVD in the heart, known as coronary microvascular dysfunction (CMD), 
can cause chronic or acute myocardial ischemia and may lead to development of heart failure. In the brain, 
cerebral SVD (cSVD)  can cause an acute stroke syndrome known as lacunar stroke, or more subtle 
pathological alterations of the brain parenchyma which may eventually lead to neurological deficits or 
cognitive decline in the long term. Coronary microcirculation cannot be visualized in vivo in humans and 
functional information can be deduced by measuring the coronary flow reserve (CFR). The diagnosis of 
cSVD is largely based on brain magnetic resonance imaging, with white matter hyperintensities, 
microbleeds and brain atrophy reflecting key structural changes. There is evidence that such structural 
changes reflect underlying cSVD. Here we review interactions between SVD and cardiovascular risk factors 
and we discuss the evidence linking cSVD with large vessel atheroma, atrial fibrillation, heart failure and 












































    
    






























































    
    




















Cardiovascular and neurological diseases are currently the leading causes of mortality and disability 4 
worldwide(1,2), and notably affect more commonly the ageing population. Combined, cardiovascular and 5 
neurological disease make up over 350 million  Disability-Adjusted Life Years, i.e. years lived in good health 6 
lost globally, per annum, and cause half of death due to non-communicable diseases around the world(2). A 7 
large proportion of death and disability attributable to these entities appears to be preventable(2). A 8 
thorough understanding of the pathophysiological bases, risk factors and eventually relation between 9 
cardiac and cerebral conditions is therefore of the outmost importance to reduce their yearly toll. Indeed, 10 
in spite of the different pathology and clinical manifestations, heart and brain disease appear to share, at 11 
least in part, some common pathophysiological features, mainly related to vascular function in both organ 12 
systems(3). The heart and brain display similarities in vascular anatomy, with large conduit arteries running 13 
on the surface of the organ providing tissue perfusion through an intricate network of penetrating small 14 
vessels. The public health burden of ischemic heart disease and cerebrovascular disease attributable to 15 
large artery pathology is well characterized(4). By contrast, the contribution of small vessel disease (SVD) is 16 
less well defined. SVD in the heart, known as coronary microvascular dysfunction (CMD), can cause chronic 17 
or acute myocardial ischemia and lead to development of heart failure(5,6). In the brain, SVD can cause an 18 
acute stroke syndrome known as lacunar stroke, or more subtle pathological alterations of the brain 19 
parenchyma including white matter hyperintensities, microbleeds and brain atrophy which may eventually 20 
lead to neurological deficits or cognitive decline in the long term(3,7). There is evidence that such structural 21 
changes reflect underlying cerebral SVD (cSVD). Among these subclinical cerebral alterations, white matter 22 
hyperintensities (WMH) are gaining increased attention due to their high prevalence in the general 23 
population and their prognostic implication(8). WMH appear as areas of signal hyperintensity in the deep or 24 
periventricular white matter, evident on brain magnetic resonance imaging (MRI) T2-weighted or Fluid-25 
Attenuated Inversion Recovery images(9). WMH are broadly equivalent to leukoaraiosis within white 26 
matter, reported on CT scans(10). WMH appear to have a vascular origin and are associated with definite 27 
alterations in cerebral small vessels, and in some reports with blood-brain barrier abnormalities or with 28 
local inflammation(8). WMH are frequently reported in individuals at high cardiovascular risk(8). Indeed, 29 
also CMD is more commonly encountered in individuals with a high burden of cardiovascular risk factors, 30 
and recently was shown to have a strong inflammatory pathophysiology(11). The Aim of the present review 31 
is to discuss the evidence linking WMH and cSVD and their potential connection with cardiovascular disease 32 
and CMD. 33 
Coronary and cerebral microcirculation 34 
 35 
The coronary arterial system comprises three compartments, each with a different function, whose 36 












































    
    


















arteries have a diameter between 5 mm and 500 μm and act as conductance vessels, accumulating blood 38 
during systole and contributing through elastic recoil to myocardial perfusion in diastole. These arteries run 39 
on the surface of the heart before branching into the myocardium giving rise to intramural vessels(12). Pre-40 
arterioles (diameter 100-500 μm) compose the intermediate compartment. Their main role is to maintain  41 
pressure at the origin of downstream arterioles within a narrow range, in response to changes in perfusion 42 
pressure or blood flow(11). Arterioles (10-100μm) are the third compartment, forming part of the 43 
microcirculation with capillaries and venules. Arterioles are the main site of myocardial blood flow 44 
regulation. They are responsible for matching myocardial oxygen demand to supply, by regulating their 45 
tone in response to signals produced by the surrounding cardiac myocytes(11,13). Coronary 46 
microcirculation cannot be visualized in vivo in humans. Functional information on the coronary 47 
microcirculation can be deduced by measuring the coronary flow reserve (CFR). This is defined as maximal 48 
myocardial blood flow (obtained during pharmacologically induced coronary vasodilation) divided by 49 
baseline myocardial blood flow. CFR reflects flow changes due to both the epicardial and microvascular 50 
compartments. In the absence of obstructive coronary artery disease, CFR is a marker of CMD. There is 51 
evidence that in the absence of obstructive coronary artery disease impairment of CFR is indicative of 52 
CMD(11).  53 
CMD can result from structural or functional alterations of the coronary microvasculature resulting in 54 
altered myocardial perfusion which manifests clinically as anginal pain and dyspnea(5). Specifically, adverse 55 
remodeling of intramural arterioles, with medial wall thickening due to increased collagen deposition and 56 
smooth muscle hypertrophy as well as some degree of intimal thickening, has been documented in patients 57 
with reduced CFR(12). Functional abnormalities leading to CMD include impaired dilatation or excessive 58 
coronary microvascular constriction, which may be due to abnormalities in endothelium-dependent as well 59 
as to endothelium-independent mechanisms(11). Aside from the obvious impact of symptoms on quality of 60 
life, CMD carries an increased risk of adverse events, including nonfatal myocardial infarction, nonfatal 61 
stroke and hospitalization for heart failure, or death(14). 62 
The cerebral circulation can be subdivided similarly into three different anatomical and functional 63 
compartments (Figure 1 Panel B). 1) cerebral arteries entering the neurocranium, acting as conductance 64 
vessels; 2) the pial circulation, which lies within the leptomeninges, and, the resistance vessels; 3) smaller 65 
penetrating arteries, arterioles and capillaries which compose the cerebral microcirculation(15). Just as for 66 
the heart, the brain lacks substantial energy reserves and therefore relies upon adequate minute-by-minute 67 
perfusion to meet its metabolic requirements. The regulation of microcirculatory resistance therefore is a 68 
key in maintaining an adequate local blood flow in the brain. On the one hand, cerebral circulation is 69 
characterized by autoregulation, the ability to maintain a broadly stable blood flow over a wide range of 70 
perfusion pressures(16). On the one hand, cerebral blood flow can selectively increase in areas of increased 71 












































    
    


















Unique to cerebral microcirculation is the presence of the blood-brain barrier (BBB), which is the functional 73 
element constituted by endothelial cells, pericytes and astrocytes connected by tight junctions, with 74 
additional contribution of endothelial transporters(18). The BBB acts as a key regulator of  trafficking of 75 
metabolites and waste products between blood and brain extracellular fluid(18). Similar to microvessels in 76 
the heart, the cerebral microcirculation cannot be imaged in human in vivo. Therefore, brain parenchyma 77 
lesions caused by SVD have been adopted as the marker for microvessel alteration(19).  78 
Cerebral SVD has been associated to a variety of brain parenchyma structural alterations, including WMH, 79 
micro- hemorrhages, disruption of myelin, lacunae, dilated perivascular spaces, reduced glial and neuronal 80 
density(19). Pathological analysis of the small arteries associated with these alterations has showed loss of 81 
smooth muscle cells from the tunica media, with thickening of the vessel wall due fibro-hyalinosis, similar 82 
to what is encountered in CMD(19,20). Microatheroma has been reported in earlier pathological reports 83 
though now is not common. There is little evidence for small vessel thrombosis. In analogy to reduced CFR 84 
in CMD, reduction of cerebrovascular reactivity, i.e. the ratio of maximal blood flow after a maximal 85 
vasodilation to basal cerebral blood flow, has been described, using various techniques, in cerebral 86 
SVD(21).  87 
Figure 2 (panel A and B) shows two non-diseased arterioles of the coronary (panel A) and cerebral (panel B) 88 
circulation.  89 
White matter hyperintensities prevalence, pathophysiology and clinical relevance 90 
 91 
WMH are amongst the most prominent and commonly encountered features in cerebral MRI. As described 92 
above, they appear as areas of signal hyperin ensity scattered in the deep or periventricular white T2-93 
weighted or FLAIR images(22). WMH can be found in MRI scans of asymptomatic individuals, and their 94 
prevalence increases with age. Indeed, while 11-21% of otherwise healthy subjects with a mean age of 64 95 
have WMH, these alterations are encountered in approximately 64-94% of otherwise healthy 96 
octogenarians(23,24). Their prevalence, is even higher in subjects with a history of cardiovascular risk 97 
factors, established cardiovascular disease or renal impairment(8,25). Compared to the frequency of WMH 98 
on imaging studies, surprisingly few pathological studies are available to date(26). Furthermore, the 99 
reliability of these studies is hampered by difficulties of matching MRI images with anatomical counterpart 100 
in post mortem evaluation and tissue-processing artifacts(26). Therefore, the neuropathological substrate 101 
of WMH is not yet defined. Earlier reports proposed demyelination and axonal loss as cardinal features of 102 
WMH(27). Diffuse vacuolation, with glial rarefaction was also described to be present in WMH(28). 103 
reduction of myelin content in WMH, therefore causing white matter “pallor”, has been described(29,30). 104 
Whether the observed pallor is due to loss of myelin sheath or to myelin content reduction secondary to 105 
neuronal loss, is still a matter of debate(31). Other studies focused on the presence of blood-brain barrier 106 












































    
    


















However, these findings are not universally supported by neuropathological studies, and some evidence 108 
exists that BBB alterations may in fact be an independent phenomenon with respect to WMH(33). Reduced 109 
blood vessel density alongside increased arteriolar wall thickening and tortuosity have been described in 110 
WMH(34). In addition to these changes on the arterial side, venular fibrosis and stenosis have been 111 
demonstrated(35).  An ischemic pathogenesis of WMH has been supported by immuno-histochemistry and 112 
gene expression profiling, which suggest a role of hypo-perfusion in the genesis of these changes(36). It is 113 
probable that reduced cerebral perfusion can cause BBB leakage and fluid extravasation that, in turn, can 114 
contribute to altered local tissue perfusion(37). Therefore, the two putative pathogenic elements are likely 115 
to be inter-dependent. A report on 3248 participants in the Framingham Heart Study, whole blood gene 116 
expression profile demonstrated a more prominent expression of inflammation-related genes in subjects 117 
with WMH, pointing at inflammation as a potential pathogenic element(38).  118 
Prognostic relevance of WMH 119 
 120 
WMH have been associated to an overall decline of superior functions, as well as with an increased risk of 121 
stroke, dementia and death(39). A high burden of WMH has been associated with gait disturbance and the 122 
risk of falls(40,41), as well as urinary symptoms(42), which contribute to increased overall disability and 123 
dependency. WMH have been shown to confer a higher risk of incident stroke (hazard ratio 3.1, 95% 124 
confidence interval 2.3-4.1) in a metanalysis comprising more than 12.500 individuals(39). The burden of 125 
WMH was also shown to be associated with stroke outcomes including all-cause mortality, functional and 126 
cognitive outcomes as well as recurrent stroke(43). WMH have been associated with a 2.15 times greater 127 
risk of developing depression in late life(44). Brain parenchymal alterations are specifically encountered in 128 
elderly subjects with low mood and in individuals with reduced interests and motivation(45). The 129 
connection between WMH and cognitive decline and dementia has been well established: a large meta-130 
analysis, including over 7500 subjects, was able to detect a 3-fold risk of incident dementia in subjects free 131 
of cognitive impairment at baseline, but with evidence of WMH on MRI(39). Other prospective studies have 132 
shown that the risk of both dementia and mild cognitive impairment is increased in the presence of 133 
WMH(46). WMH lower the onset of overt dementia in a variety of neurodegenerative diseases(47). 134 
coexistence of neurodegenerative forms of dementia, in particular Alzheimer’s Disease (AD), with 135 
cerebrovascular disease and vascular forms of cognitive impairment is well described(48). recent work has 136 
shown that younger individuals carrying an AD-causing  autosomal dominant mutation exhibit WMH, and 137 
these are evident well before onset of AD symptoms(49).  138 
Cardiovascular diseases, WMH and CMD 139 
An ever-growing amount of data is building inking cardiovascular disease with dysfunction in the 140 
microvasculature of both the heart and the brain. The following sections discuss currently available data on 141 












































    
    


















for their relationship and Tables 1 and 2 provide a summary of the most relevant studies. 143 
Cardiovascular risk factors and SVD 144 
 145 
Cardiovascular risk factors are well known to negatively impact on vascular function throughout the body. 146 
Their contribution to overall cardiovascular disease is high, and strategies aimed at the reduction of 147 
cardiovascular risk factor burden are effective in reducing cardiovascular morbidity and mortality.(50) Not 148 
surprisingly, microvascular dysfunction in the coronary and cerebral circulation are sensitive to 149 
cardiovascular risk factors, itemised below. 150 
Hypertension 151 
Hypertension is the risk factor which has been shown to have the strongest association with WMH. In an 152 
early report by Wisemann et al. on approximately 150 subjects, hypertension was associated with a higher 153 
overall burden of periventricular and subcortical WMH(51). In 1352 subjects free of dementia included in 154 
the Framingham Offspring Study, the presence of arterial hypertension in midlife, was associated with 155 
accelerated WMH progression on follow up(52). In another, larger cohort from the same study, (n=1814), 156 
hypertension and increased left ventricular mass, a marker for hypertension-related damage in the 157 
cardiovascular system, were associated with WMH burden(53). 158 
Just as signs of cerebral SVD are more frequently encountered in hypertensive subjects, individuals with 159 
high blood pressure were shown to have impaired CFR. In their seminal study, Gimelli and colleagues 160 
elegantly showed that untreated hypertensive individuals have significantly reduced maximal coronary 161 
blood flow and CFR when compared with normotensive subjects(54). Subsequent work showed that the 162 
reduction of CFR is due to a transmural impairment of maximal blood flow and is directly proportional to 163 
systolic blood pressure values(55). Further, CMD due to adverse structural remodeling of intramyocardial 164 
arterioles contributed to the observed impairment of CFR(11). Initiation of anti-hypertensive treatment 165 
improved CFR in these subjects(56). Figure 2 (panel C and D) shows arteriolar remodeling of the coronary 166 
(panel C) and cerebral (panel D) arterioles in patients with arterial hypertension.  167 
Hypercholesterolemia 168 
The role of blood cholesterol on the development of WMH is less well defined when compared to 169 
hypertension. In a large cohort comprising 1135 subjects with a history of ischemic stroke, Jimenez-Conde 170 
and colleagues showed an association between hyperlipidemia, defined as hypercholesterolemia, 171 
hypertriglyceridemia or current lipid-lowering treatment, and lower levels of WMH(57). By contrast, in a 172 
Chinese cohort of 4683 hospitalized subjects plasma low density lipoprotein (LDL) cholesterol was 173 
associated with an increased burden of WMH(58). This is consistent with the recent finding that subjects 174 
affected by familial hypercholesterolemia have an increased burden of WMH when compared to healthy 175 
controls(59). A recent trial on 732 hypertensive individuals has shown a significant reduction in WMH 176 












































    
    


















additive with that of blood pressure lowering medications(60).   178 
In their seminal paper, Yokoyama and colleagues first reported reduced CFR in hypercholesterolemic 179 
individuals with normal epicardial coronary arteries(61). Subsequent evidence showed that plasma LDL 180 
cholesterol concentration was indeed the subfraction more strongly associated with reduced CFR, an effect 181 
which was shown to be, at least partially, reversed by lipid-lowering medications, suggesting a causal 182 
relationship(62,63).  183 
Insulin Resistance and Diabetes 184 
There appears to be a relation between WMH and altered insulin sensitivity, though this is incompletely 185 
characterized. A large study of 1232 subjects with manifest arterial disease has shown that individuals 186 
(n=451) with evidence of metabolic syndrome did not have increased burden of WMH, despite being at 187 
higher risk for cognitive impairment when compared to healthy controls(64). At va iance, a significant 188 
association between hyperglycemia or diabetes and WMH burden was found in a larger cohort consisting of 189 
1597 young adults (mean age 40 years)(65). On the other hand, insulin resistance did not predict WMH 190 
progression at 10 years of follow up in a cohort of 932 individuals from the Atherosclerosis Risk in 191 
Community (ARIC) study(66). Similarly, glycemic control was not significantly associated with WMH in type 192 
2 diabetic patients enrolled in the Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes 193 
(ACCORD MIND) trial at 40 months of follow up(67). 194 
Hyperglycemia impairs endothelial function, even in healthy individuals(68). Indeed, diabetes mellitus and 195 
hyperglycemia have been consistently associated with reduced CFR, measured with various techniques and 196 
with the use of different vasodilators(69,70). the few available data on glucose-lowering drugs have been 197 
inconsistent in reporting an improvement in CFR(71,72). 198 
Cigarette Smoking 199 
Smoking was associated with accelerated WMH progression on long term follow up in the Framingham 200 
Offspring Study(52). In a subsequent report on 972 subjects from the ARIC Study, the risk of WMH 201 
progression was proportional to the lifetime exposure to cigarette smoking, measured in pack-years(73). 202 
Smoking was shown to substantially contribute to altered coronary microvascular function, with 203 
detrimental effects on CFR detectable after the first few cigarettes(74,75). As shown by Kaufmann and 204 
colleagues, high doses of antioxidants rapidly reversed coronary blood flow impairment in smokers, 205 
suggesting increased oxidative stress as the cause of smoking-induced microvascular dysfunction(74). 206 
Carotid Atherosclerosis and SVD 207 
Carotid atherosclerosis is common in the general population, with an estimated prevalence reaching up to 208 
40% in otherwise healthy middle-age adults in some series(76). In addition to being a known etiologic factor 209 
for around 20% of ischemic strokes(77), carotid atherosclerosis is associated with cSVD and with WMH and 210 












































    
    


















sectional studies comprising 5306 subjects showed a significant association between the presence of 212 
carotid artery plaques and WMH(79). The potential atheroembolic etiology of WMH has been suggested by  213 
small studies showing an association between the presence of WMH and an ipsilateral vulnerable carotid 214 
artery plaque(80). However, vascular risk factors may be the confounding variables underlying the observed 215 
associations(8). In a recent publication by our group, carotid plaque features were not associated to WMH 216 
progression in asymptomatic subjects at intermediate-high cardiovascular risk with non-critical carotid 217 
stenosis at 20 month follow up(81). The relationship between CMD and carotid atherosclerosis has been 218 
less investigated. Indeed reports of reduced CFR in individuals with different stages of carotid 219 
atherosclerosis exist in the literature(82,83). Considering that, in the case of CMD, no direct pathogenic role 220 
for carotid plaque may be hypothesized, it is likely that cardiovascular risk factors mediate the link between 221 
carotid atherosclerosis and reduced CFR. Figure 4 shows FLAIR images on MRI scans for the identification of 222 
WMH of two subjects at baseline and at 20 months. 223 
Atrial fibrillation and SVD 224 
Atrial fibrillation (AFib) is the most common disorder of the heart rhythm(84). It contributes to a substantial 225 
proportion of ischemic strokes in the general population, and has been associated with the development of 226 
cognitive impairment(85,86). A growing body of evidence is building linking AFib and WMH. Kobayashi et al 227 
first reported increased WMH in AFib patients when compared to age and sex matched controls in a cohort 228 
of 142 subjects(87). Gaita and colleagues reported an increased risk of WMH in subjects with AFib when 229 
compared to controls (odds ratio 11, 95% confidence interval 6 to 21)(88). Patients with paroxysmal AFib 230 
had less WMH when compared to those with persistent AFib(88). This is consistent with the higher risk of 231 
thromboembolic events observed in persistent versus paroxysmal AFib, and supports the hypothesis that 232 
part of the observed WMH could be related to subclinical embolism(89). However, in another observational 233 
study on 234 stroke patients, an increased burden of WMH was found in AFib subjects specifically localised 234 
in the anterior subcortical white matter(90). Due to the specificity of the WMH pattern and the lack of 235 
relation with embolic distribution, Mayasi and colleagues put forward the hypothesis that the link between 236 
AFib and WMH may extend beyond thromboembolism, and in fact may be due to a more global cardio-237 
vasculopathy(90). 238 
Few data currently exist on CMD and AFib. Currently available reports have consistently shown a reduction 239 
in maximal coronary blood flow with increased microvascular resistance, both parameters being markers of 240 
CMD(91,92). These alterations persisted after conversion to sinus rhythm, and therefore appeared not to 241 
be strictly arrhythmia-related, but possibly the expression of underlying endothelial dysfunction(91).  242 
Heart failure and SVD 243 
Heart failure (HF) has been consistently associated with cognitive impairment and dementia, possibly due 244 
to the high comorbidity burden that is generally encountered in HF patients, and possibly to impaired 245 












































    
    


















In an early report by Vogels and colleagues, HF patients had a higher burden of WMH when compared to 247 
individuals with established cardiovascular disease(93). Left ventricular ejection fraction was shown to be 248 
an independent predictor of WMH burden in HF subjects(93). A subsequent report on 69 HF patients 249 
confirmed the association between reduced cerebral perfusion and WMH burden(94). 250 
As extensively reviewed elsewhere(6), CMD is an hallmark of HF, both HF with preserved and with reduced 251 
ejection fraction. Indeed, the synergistic effect of multiple cardiovascular risk factors and the low-grade 252 
inflammatory milieu often found in subjects with cardiac conditions, was shown to impair the function of 253 
coronary microcirculation. Ischemia secondary to CMD is a major contributor to structural and functional 254 
myocardial impairment in HF with preserved ejection fraction, but also to contribute to myocardial 255 
dysfunction in HF with reduced ejection fraction(11,95). 256 
Heart valve disease and SVD 257 
Substantial evidence on the association between heart valve disease an SVD is lacking. In 232 subjects with 258 
significant chronic valve disease, Lee and colleagues report an association between WMH burden and right 259 
atrial pressure(96). Therefore, they postulate a reduced perfusion pressure and increased capillary 260 
hydrostatic pressure, secondary to increased venular pressure in the context of high right atrial pressure, as 261 
a potential mechanism for WMH genesis in heart valve disease(96). As for what concerns CMD, severe 262 
calcification causing aortic stenosis has been associated with reduced CFR(11). A possible reason for that 263 
could be the increased left ventricular wall tension in the setting of increased afterload, with both reduced 264 
coronary perfusion pressure and increased microvascular resistance due to extrinsic compression of the 265 
microvasculature(6,11). 266 
Congenital heart disease and SVD 267 
Congenital heart disease may be associated with major cardiac dysfunction and potentially with impaired 268 
systemic blood oxygenation. Patients with Eisenmenger syndrome were shown to have increase WMH, 269 
possibly again attributable to impaired cerebral oxygenation(97). 270 
Interestingly, to date no study has investigated CMD selectively in congenital heart disease. However, 271 
evidence exists that the stressors of hypoxia and cardiopulmonary bypass do alter endothelia and 272 
microvascular function systemically(98).  273 
Treating microvascular dysfunction 274 
There is relatively little high-quality data from randomized controlled trials on the treatment of 275 
microvascular dysfunction and on the prevention of further accumulation of WMH. Based on the 276 
observations reported above, approaches aimed at reducing the overall burden of cardiovascular risk 277 
factors could be advocated. Adopting a healthy lifestyle incorporating a diet rich in fruits and wholegrains, 278 
limiting high salt foods, sugary drinks and alcohol consumption, avoiding cigarettes smoking and 279 
incorporating daily exercise has proven efficacy on reducing blood pressure and cholesterol concentrations, 280 












































    
    


















approach in preventing SVD, the observation that overall cardiovascular risk factors burden in early 282 
adulthood is associated to WMH development justifies advocating a lifestyle that limits risk factors 283 
exposure(99). Angiotensin Converting Enzyme inhibitors (ACE-i) and statins were shown to improve 284 
endothelial function and to significantly improve microvascular function in CMD(100). While less evidence 285 
is available for cSVD, modulation of the renin-angiotensin-aldosterone axis and statin use has proven 286 
efficacy in limiting WMH progression(60). Antiplatelet medications may be indicated in particular if large-287 
vessels atherosclerosis is detected. Indeed, inhibition of thromboxane A2 pathway by low-dose aspirin has 288 
shown to reduce microvascular constriction and local thrombosis(100). The use of phosphodiesterase type 289 
3 inhibitor cilostazol, an antiplatelet medication with vasodilating properties, was shown to improve 290 
CFR(100). Preliminary data on animal models suggest that cilostazol may improve cerebral microvascular 291 
and BBB(101). Other approaches have been proposed, targeting hyperglycemia, inducing vasodilation or 292 
modulating inflammation, but so far they remain experimental(100). 293 
Future perspectives 294 
The complex interplay between cardiovascular and nervous systems is gaining increasing attention, and the 295 
central role of the microcirculation is currently an area of active investigation. Several studies are underway 296 
to define strategies to abate SVD burden. These include lifestyle modification including aerobic exercise to 297 
prevent WMH and improve cognitive function across different age categories (see ClinicalTrials.gov 298 
NCT02729428). Pharmacological approaches with the use of cilostazol to improve blood vessel health are 299 
being tested in randomized controlled trials (see ClinicalTrials.org NCT01932203). in both CMD and cSVD, 300 
vasodilator drugs are being tested, inclu ing PDE3 and PDE5 inhibitors and ETA antagonists 301 
(ClinicalTrials.org NCT03855332, NCT04097314 and NCT02450253). Furthermore, studies are being carried 302 
out to directly evaluate the relationship between coronary and cerebral microcirculation (see 303 
ClinicalTrials.go NCT04131075). 304 
Conclusions 305 
 306 
The heart and the brain both rely on fine tuning of blood flow to match rapid changes in metabolic 307 
demand. Blood flow regulation requires adequate functioning of the microcirculation in both organs, with 308 
loss of adequate small vessel function leading to clinical manifestations including chest pain, dyspnea, heart 309 
failure, lacunar ischemia, WMH, cognitive impairment and dementia. Small vessel disease in the heart and 310 
in the brain appear to share some common pathophysiological aspects, as can be inferred from the 311 
presence of common risk factors and common morphological features of the diseased vessels. Further 312 
studies are needed to elucidate the relation between cerebral and cardiac microvessels and to evaluate 313 
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Figure 1. Structural and spatial organization of cardiac and cerebral circulations 
 
Panel A. Resin cast of the coronary circulation, showing large epicardial conductance arteries branching 
down to penetrating small vessels (reproduced with permission from Camici PG, and Rimoldi OE J Nucl Med 
2009;50:1076-1087) 
Panel 2. Resin cast of the cerebral circulation Large, superficial cerebral arteries give origin to pial and 
penetrating vessel, providing blood flow to brain parenchyma (reproduced with permission from Zlovovich 
BV et al, Neurosurgey 1998;43:877-878). 
 
Figure 2. Small arteries of the heart and brain 
 
Panel A. Small artery, healthy human myocardium. Male aged 27 y. Hematoxylin and eosin stained section, 
kindly provided by Mary Sheppard & Joe Westaby, St George’s Cardiac Pathology group. 
Panel B. Small artery, healthy human brain subcortical white matter. Male aged 56 y. Hematoxylin and 
eosin stained section, tissue kindly provided by Margaret Esiri, Oxford Brain Collection. Bar=20 microns. 
Panel C. Adverse remodelling of intramural coronary arteriole in a patient with arterial hypertension 
resulting in medial wall thickening, mainly due to smooth muscle hypertrophy and increased collagen 
deposition, with variable degrees of intimal thickening. This is the anatomical substrate underlying the 
abnormal coronary physiology and blood flow in these patients. Masson trichrome stained section. Bar=100 
microns. (Courtesy of Prof Giulia D’Amati, Sapienza University, Rome). 
Panel C. Small penetrating arteries exhibiti g cerebral small vessel disease, human brain subcortical white 
matter. Green: fibrous connective tissue, Masson trichrome stained section. Bar=100 microns. Tissue kindly 
provided by Margaret Esiri, Oxford Brain Collection. 
 
Figure 3. Proposed model for the relationship between cardiovascular disease, white matter 
hyperintensities and coronary microvascular dysfunction. 
Cardiovascular risk factors all contribute to endothelial dysfunction which in turn causes microvessels 
alterations, in terms of functional impairment or adverse vascular remodeling. Altered structure and 
function of the microcirculation is the basis of coronary microvascular disease (CMD) and cerebral small 
vessels disease (cSVD). Carotid atherosclerosis is associated to cSVD, to which it may contribute through 
microembolization. On the other hand, atherosclerosis and carotid plaque development share the same risk 
factors. Atrial fibrillation is associated to cSVD, and again microembolization has been put forward as a 












































    
    


















and possibly reduces perfusion pressure both in the coronary and cerebral arteries. Finally, congenital heart 
disease was shown to be associated to cSVD, possibly due to cerebral hypoperfusion and due to the effects 
of heart and lung machine in early heart surgery. Cardiopulmonary bypass was shown to alter endothelial 
function systemically.  
CMD is commonly found in heart failure, and it appears to contribute to its pathogenesis and progression. 
Heart failure per se may afterwards contribute to cSVD through reduced cerebral perfusion. 
 
Figure 4. Fluid attenuated inversion recovery images (FLAIR) of two subjects affected by non-critical 
carotid atherosclerosis 
Subject A had a minimal white matter hyperintensities (WMH) burden, with no progression after 20 
months. Subject B had a higher burden of WMH (note the hyperintense, patchy areas of the deep white 
matter, more prominent around the posterior horns of the lateral ventricles), with evidence of progression 
(red region of interest) after follow up. Both individuals had non-critical carotid atherosclerosis, no plaque 































































d.Table 1. Summary of selected publications concerned with the relationship between white matter hyperintensities and cardiovascular diseases  
Abbreviations. AFib= atrial fibrillation; BP= blood pressure; FH= familial hypercholesterolemia; HR= hazard ratio;    HTN=hypertension; LVEF= left ventricular 
ejection fraction; OR=odds ratio; SBP= systolic blood pressure; WMH= white matter hyperintensities. 
Condition Study n Main findings Ref 
Hypertension Debette et al, 2011 1352 HTN, i.e. SBP>140 mHg or current BP lowering me ications, at a mean age of 54 years 
old were associated with WMH progression during 7 year follow up (β ± SE = 0.23 ± 
0.06, p < 0.001). 
51 
 Jeerakatil et al, 2004 1814 HTN (R= 0.473, p<0.0001) is associated with WMH load. Cigarette  smoking (avg daily 
cigarettes 5.2±11.2 vs 3.1±8.7, p<0.001) are associated with the presence of large 
WMH. 
52 
Dyslipidemia Todate et al, 2019 63 WMH were more common in subjects with familial hypercholesterolemia than in 
healthy controls (controls, 0% vs. FH, 14.2%, p=0.02) at a mean age of 49. 
58 
 Zhang et al, 2019 732 Low-dose Rosuvastatin significantly reduced new WMH and cognitive impairment with 
respect to placebo at 59.8 months of follow up in a cohort of hypertensive elderly 
(HR=0.500; 95% CI: 0.34-0.74, p<0.001 and HR=0.54; 95% CI: 0.36-0.80, p=0.002, 
respectively). 
59 
Diabetes Weinstein et al, 2015 1597 Diabetes was associated to increased WMH volume in subjects with mean age of 40 
years (β ± SE = 0.22 ± 0.09, p=0.015). 
64 
 De Havenon et al, 2019 816 Effective intensive glycemic control (lower HbA1C) was not associated with reduced 
WMH progression over 40 months (p=0.916). 
66 
Smoking Power et al, 2015 972 Active cigarette smoking was associated with WMH progression at 6 years follow up 
(OR 1.52; 95% CI 1.01-2.30). Probability of WMH progression increased with pack/year 
(OR 1.21; 95% CI 1.04-1.41). 
72 
Carotid atherosclerosis Moroni et al, 2016 5306 Carotid atherosclerosis was associated with the presence of WMH in a meta-analysis of 
cross-sectional studies (OR 1.42, 95% CI 1.22-1.66, p<0.0001). 
78 
 Ammirati et al, 2019 51 No association between carotid plaque features of vulnerability (including plaque 
density, plaque neovascularization, microcalcification or remodeling) and WMH 
progression at 20 months of follow up (all p>0.05). 
80 
Atrial Fibrillation Gaita et al, 2013 270 WMH were more common in AFib subjects when compared to healthy age, sex-
matched controls (OR 11, 95% CI 6-21; p<0.001). Persistent AFib patients had a higher 
WMH burden with respect to paroxysmal AFib (WMH number 41.1 ± 28.0 vs. 33.2 ± 
22.8, p = 0.04). 
87 


































































anterior subcortical WMH (OR 3.647, 95% CI 1.681 to 7.911, p=0.001).  
Heart failure Vogels et al, 2007 148 Heart failure is significantly associated with an increased burden of WMH compared to 
controls (p<0.001). LVEF correlated significantly with WMH burden (R=-0.495, 
0<0.001). 
92 
 Alosco et al 2013 69 Reduced cerebral perfusion, measured as peak flow velocity of the middle cerebral 
artery, was associated to increased WMH burden in subjects with heart failure (β=-
0.34, p=0.02) 
93 
Valvular heart disease Lee et al, 2018 232 Among patients with significant heart valve disease, right atrial pressure was linearly 






























































d.Table 2. Summary of selected publications concerned with the relationship between coronary microvascular dysfunction and other cardiovascular diseases  
ACEi= angiotensin converting enzyme inhibitor; AFib=atrial fibrillation; CC-IMT= common carotid intima-media thickness; CFR= coronary flow reserve; 
HTN=hypertension; LDL= low density lipoprotein cholesterol; LVH= left ventricular hypertrophy; MBF= maximal blood flow; For an updated and in-depth review 
of coronary microvascular dysfunction in Heart Failure see ref 94. 
 
Condition Study n Main findings Ref 
Hypertension Rimoldi et al, 2014 40 CFR was reduced in subjects with HTN and LVH when compared to healthy controls. 
CFR reduction was mainly due to MBF impairment (subepicardial MBF 3.07 ml/min per 
g vs 1.76 ml/min per g, p<0.001, subendo ardial MBF 3.18 ml/min per g vs 1.91 ml/min 
per g, p<0.001) 
54 
 Masuda et al, 2000 12 ACEi initiation increases MBF in subjects with hypertension after 12 weeks of 
treatment (1.77 vs 1.70; p non significant). Coronary resistance was shown to 
significantly decrease p<0.003. 
55 
Dyslipidemia Kaufmann et al, 2000 80 LDL was shown to negativ ly correlate with CFR in hypercholesterolemic subjects (r=-
0.61, p<0.05) 
61 
Diabetes Yokoyama et al, 1997 37 CFR is significantly reduced in subjects with non-insulin dependent diabetes mellitus 
(2.77±0.85 vs 3.8±1.0, p<0.01). 
67 
Smoking Kaufmann et al, 2000 19 CFR was reduced in 3 (21%) of the 11 smokers and none of the 8 controls (p<0.05). 
High dose of vitamin C normalized CFR in smokers (p<0.05). 
73 
Carotid atherosclerosis Sen et al, 2009 60 CC-IMT was higher in subjects with microvascular angina compared to control subjects 
(0.71 ± 0.11 vs 0.60 ± 0.16 <0.01). Subjects with microvascular angina were also more 
likely to have carotid artery plaques (33% vs 10%, p=0.03) 
82 
Atrial Fibrillation Wijesurendra et al, 2018 74 MBF was reduced in AFib patients both under resting and stress conditions (p=0.044 
and p<0.001 respectively). Rest and stress MBF did not change 6 to 9 months after 























































    
    
    
    
    
    
    
    






























































    
    
    
    
    
    
    
    






























































    
    
    
    
    
    
    
    
























Hemodynamic impact on 
microcirculation
Heart failure
Features CMD. May contribute to 
cSVD through reduced perfusion
Congenital Heart Disease
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